Together, these findings identify Axl as a driver of liver fibrosis by activating HSCs, whereas MerTK on macrophages acts as a pro-fibrotic in NASH-driven fibrosis and possesses an anti-fibrotic role in CCl4-driven fibrosis through apoptotic cell clearance. Here, MERTK is linked to metabolic dysfunction-associated steatohepatitis.